Intellia Therapeutics: Chardan Capital Keeps Buy Rating, Cuts PT to $60

Intellia Therapeutics: Chardan Capital Keeps Buy Rating, Cuts PT to $60

In a recent update, Chardan Capital has maintained its buy rating on Intellia Therapeutics (NASDAQ:NTLA) while lowering its price target (PT) to $60 from $68. This adjustment follows a series of recent developments and analyst revisions surrounding the biotechnology company [2].

Chardan Capital's decision to keep the buy rating indicates confidence in Intellia's development pipeline and market potential. The firm's PT cut, however, reflects a more cautious outlook on the stock's immediate valuation. Intellia Therapeutics, a genome editing company, has been making strides in its clinical trials and pipeline, which has drawn significant attention from investors and analysts alike.

Intellia's stock has been volatile, trading at $10.73 as of the latest data, significantly below analyst targets ranging from $7 to $106. Despite the recent volatility, the company's strong balance sheet and promising pipeline continue to attract investor interest. Intellia has been actively progressing its development programs, including NTLA-2001 for transthyretin amyloidosis, NTLA-2002 for hereditary angioedema, and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease [1].

The company has also been making headway with its nex-z treatment for ATTR-PN, with enrollment in the MAGNITUDE-2 study expected to be completed in the first half of 2026. This development could pave the way for a Biologics License Application (BLA) filing in or before 2028. Additionally, Intellia plans to present longer-term data from its Phase 1 study at the 5th International ATTR Amyloidosis Meeting for Patients and Doctors on September 25-26, 2025, in Baveno, Italy [1].

The recent earnings report for Intellia Therapeutics, released on August 7, 2025, showed an earnings per share (EPS) of -$0.99, beating analysts' consensus estimates of -$1.03. Revenue reached $14.25 million, exceeding the anticipated $12.26 million. These results reflect a positive earnings surprise for the company [2].

Intellia's stock has also seen insider activity, with EVP Edward J. Dulac III selling 7,462 shares on July 23, 2025. This sale represents a 6.57% decrease in his position, but insiders still hold 3.10% of the company's stock [2].

Chardan Capital's decision to maintain a buy rating while lowering the PT reflects a balanced view of Intellia's prospects. The company's strong pipeline and recent developments continue to make it an attractive investment opportunity, despite the current market volatility and analyst target adjustments.

References:
[1] https://www.investing.com/news/analyst-ratings/intellia-therapeutics-stock-price-target-lowered-to-45-by-wells-fargo-93CH-4179979
[2] https://www.marketbeat.com/instant-alerts/royal-bank-of-canada-issues-pessimistic-forecast-for-intellia-therapeutics-nasdaqntla-stock-price-2025-08-08/